Literature DB >> 28605875

miR-1254 promotes lung cancer cell proliferation by targeting SFRP1.

Hong Li1, Tian Yang1, Dong Shang1, Zhongmin Sun2.   

Abstract

Lung cancer is the leading cause of cancer deaths worldwide, many miRNAs play critical role in lung cancer initiation and progression. Here, we demonstrated that miR-1254 was upregulated in lung cancer tissues and cells. miR-1254 overexpression promoted lung cancer cell proliferation determined by MTT assay, colony formation assay, soft agar growth ability assay and BrdU incorporation assay, miR-1254 knockdown suppressed lung cancer cell proliferation. Mechanism analysis revealed that Wnt/β-catenin pathway antagonist secreted frizzled related protein 1 (SFRP1) was its target, its expression was opposite to SFRP1 level, and directly bound to the 3'UTR of SFRP1. Double knockdown of miR-1254 and SFRP1 promoted lung cancer cell proliferation, suggesting miR-1254 promoted lung cancer cell proliferation by targeting SFRP1.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cell proliferation; Lung cancer; SFRP1; miR-1254

Mesh:

Substances:

Year:  2017        PMID: 28605875     DOI: 10.1016/j.biopha.2017.05.116

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  13 in total

1.  Cisplatin and phenanthriplatin modulate long-noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/β-catenin and TGF-β signaling.

Authors:  Jerry D Monroe; Satya A Moolani; Elvin N Irihamye; Katheryn E Lett; Michael D Hebert; Yann Gibert; Michael E Smith
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

2.  miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression.

Authors:  Xiaogang Peng; Li Guan; Baoan Gao
Journal:  Onco Targets Ther       Date:  2018-12-07       Impact factor: 4.147

3.  MiR-1254 Functions as a Tumor Suppressor in Oral Squamous Cell Carcinoma by Targeting CD36.

Authors:  Ruixue Chen; Yang Zhang; Xudong Zhang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

4.  The MicroRNA hsa-let-7g Promotes Proliferation and Inhibits Apoptosis in Lung Cancer by Targeting HOXB1.

Authors:  Fenghe Cui; Qian Zhou; Kuang Xiao; Shengwei Ma
Journal:  Yonsei Med J       Date:  2020-03       Impact factor: 2.759

5.  Neuroepithelial Cell Transforming Gene 1 Acts as an Oncogene and Is Mediated by miR-22 in Human Non-Small-Cell Lung Cancer.

Authors:  Shengguang Ding; Haitao Huang; Yiming Xu; Liang Shen; Chongjun Zhong; Shiying Zheng
Journal:  Biomed Res Int       Date:  2020-01-11       Impact factor: 3.411

6.  miR-1254 inhibits progression of glioma in vivo and in vitro by targeting CSF-1.

Authors:  Xin Li; Shiqi Kong; Yingxiao Cao
Journal:  J Cell Mol Med       Date:  2020-01-28       Impact factor: 5.310

7.  Upregulation of miR-1254 promotes Hepatocellular Carcinoma Cell Proliferation, Migration, and Invasion via Inactivation of the Hippo-YAP signaling pathway by decreasing PAX5.

Authors:  Xu Lu; Chao Yang; Yuanchang Hu; Jian Xu; Chengyu Shi; Jianhua Rao; Weixin Yu; Feng Cheng
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

8.  miR-1254 induced by NESG1 inactivates HDGF/DDX5-stimulated nuclear translocation of β-catenin and suppresses NPC metastasis.

Authors:  Chao Cheng; Wenmin Li; Xuemei Peng; Xiong Liu; Ziyan Zhang; Zhen Liu; Tongyuan Deng; Rongcheng Luo; Weiyi Fang; Xiaojie Deng
Journal:  Mol Ther Methods Clin Dev       Date:  2021-02-04       Impact factor: 6.698

9.  Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.

Authors:  Ivonne Regel; Melanie Eichenmüller; Ujjwal Mukund Mahajan; Beate Hagl; Simone Benitz; Beate Häberle; Christian Vokuhl; Dietrich von Schweinitz; Roland Kappler
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-18       Impact factor: 4.553

10.  Comprehensive Analysis of the Expression and Prognosis for SFRPs in Breast Carcinoma.

Authors:  Zeng-Hong Wu; You-Jing Zhang; Jian-Xin Yue; Tao Zhou
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.